• Vaccine Name: mouse/human gp10025-33 peptide plus CpG adjuvant; mouse/human gp100; mouse/human gp10025-33 peptide-pulsed DCs
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007644
• Type: peptide, DC
• Status: Licensed
• Preparation: C57BL/6J mice were challenged subcutaneously with B16F10 melanoma cells, after vaccination . Alternatively, a neutralizing anti-IL-10 monoclonal antibody (mAb) was subcutaneously administered at the site of tumor challenge to counteract regulatory cells. Finally, combinatorial treatment was performed associating human gp10025-33 peptide-pulsed DC vaccination with administration of the anti-IL-10 mAb (Kalli et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: T-cell tumor infiltrates showed an increase of CD4+granzyme+ T-cells and a decreased number of CD4+CD25+Foxp3+ Treg elements from mice treated with either gp10025-33 peptide-pulsed DC vaccination or anti-IL-10 mAb administration (Kalli et al., 2013).